ME/CFS Skeptic
Senior Member (Voting Rights)
Split from Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome A Randomized Controlled Trial, 2004, Blacker et al.. The quote in this post refers to the Blacker paper.

It's the main result of an open-label study by Vermeulen et al. published in 2004. They tested the use of acetylcarnitine (ALC), propionylcarnitine (PLC), or a combination of both (ALC + PLC) in a crossover design. At 24 weeks of treatment 59% in the ALC group, 63% in the PLC group, and 37% in the ALC + PLC group reported to be improved.
Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome - PubMed (nih.gov)
After 24 weeks of therapy, the medication was stopped and all patients returned 2 weeks later for follow-up. As you can see in the table, the % of patients reporting to be improved suddenly dropped to zero.
This might also be of interest.This study may be useful when explaining the issues with subjective outcomes in unblinded trials with inadequate controls.

It's the main result of an open-label study by Vermeulen et al. published in 2004. They tested the use of acetylcarnitine (ALC), propionylcarnitine (PLC), or a combination of both (ALC + PLC) in a crossover design. At 24 weeks of treatment 59% in the ALC group, 63% in the PLC group, and 37% in the ALC + PLC group reported to be improved.
Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome - PubMed (nih.gov)
After 24 weeks of therapy, the medication was stopped and all patients returned 2 weeks later for follow-up. As you can see in the table, the % of patients reporting to be improved suddenly dropped to zero.
Last edited by a moderator: